USPTO serial 79434015
TREEFROG THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCDORMAN, ROGER THOMAS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with TREEFROG THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Stem cells for research; stem cells for scientific purposes; nutrition agents, namely, cell culture reagents for scientific and research use for processing living cells other than for medical purposes; cell culture media other than for medical purposes; delivery media for scientific and research use for the delivery of cells cultures other than for medical purposes; micro-tissues obtained from stem cells for research purposes; cell aggregates for research; culture matrix being cell culture media for scientific research purposes | ACTIVE | — |
| 005 | Pharmaceutical products for the treatment of Parkinson's disease and neurodegenerative diseases, heart disease, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury, skin burns, spinal cord injuries, huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, viral diseases, namely, HIV (Human Immunodeficiency Virus), HTLV-1 (Human T-lymphotropic Virus Type 1), Hepatitis B, Hepatitis C, Epstein-Barr Virus, Cytomegalovirus, SARS-CoV-2, Varicella-Zoster Virus, Herpes Simplex Virus, Measles Virus, autoimmune diseases, namely, Type 1 Diabetes, Multiple Sclerosis, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus, Graves' Disease, Dermatitis, Allergic Eczema, immunodeficiency syndromes, cancers, inflammatory diseases, namely, Psoriasis, Atopic Dermatitis, Eczema, Crohn's Disease, Ulcerative Colitis, Asthma, Ankylosing Spondylitis, Macrophage Activation Syndrome, Hemophagocytic Lymphohistiocytosis; pharmaceutical preparations for the treatment of Parkinson's disease and neurodegenerative diseases, heart disease, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury, skin burns, spinal cord injuries, huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, viral diseases, namely, HIV (Human Immunodeficiency Virus), HTLV-1 (Human T-lymphotropic Virus Type 1), Hepatitis B, Hepatitis C, Epstein-Barr Virus, Cytomegalovirus, SARS-CoV-2, Varicella-Zoster Virus, Herpes Simplex Virus, Measles Virus, autoimmune diseases, namely, Type 1 Diabetes, Multiple Sclerosis, Hashimoto's Thyroiditis, Rheumatoid Arthritis, Psoriasis, Systemic Lupus Erythematosus, Graves' Disease, Dermatitis, Allergic Eczema, immunodeficiency syndromes, cancers, inflammatory diseases, namely, Psoriasis, Atopic Dermatitis, Eczema, Crohn's Disease, Ulcerative Colitis, Asthma, Ankylosing Spondylitis, Macrophage Activation Syndrome, Hemophagocytic Lymphohistiocytosis; pharmaceutical preparations for tissue regeneration; stem cells for medical or veterinary use; pluripotent stem cells intended for cell and gene therapies; cell culture media for medical or veterinary use; surgical implants comprised of living tissues obtained from stem cells; cell growth media for growing cells for medical use; culture matrices for medical or veterinary use; micro-tissues for use in reducing inflammation, regenerating and replacing cells, tissues and organs | ACTIVE | — |
| 009 | Scientific apparatus, namely, cytometers and biomimetic 3D culture systems composed of cell culture dishes for cell culture systems; scientific apparatus, namely, laboratory pipettes and capsules for the analysis and sorting of cell culture; bioreactors for cell culture; observation apparatus, namely, microscopes for cell culture; incubators for cell culture; cell culture apparatus for laboratory use, namely, cell culture dishes and tissue culture flaks; downloadable software used for the collection, analysis, sorting, communication of biological information relating to stem cells; measuring apparatus for controlling the quality of cell production by encapsulation; cell or molecule encapsulated lines being cell encapsulation apparatus for laboratory use, for the microencapsulation, culture and large-scale production of stem cells; microscopes; microfluidic systems being System on a chip (SoC) for parallelizing chips; microfluidic chip connectors being connectors for microfluidic devices used in cell culture and analysis | ACTIVE | — |
| 010 | Apparatus for stem cell regeneration for medical use; apparatus for cell culture systems for medical purposes, namely, cell culture chambers and capsules; apparatus for cell culture systems by encapsulation for medical purposes; apparatus for analyzing and sorting cell culture for medical purposes, namely, cell culture chambers and capsules | ACTIVE | — |
| 042 | Laboratory research in the field of biotechnology; scientific research on stem cells; scientific research on the production of pluripotent stem cells by encapsulation; scientific research on the differentiation of pluripotent stem cells into differentiated cells; research and development in the field of stem cells, cell and gene therapy and biotechnology; pharmaceutical research and development; scientific laboratory services; providing information with respect to scientific research in the field of stem cells, cell and gene therapy and biotechnology; software development in the field of biotechnology and cell therapy; research on controlling the quality of the production of cells by encapsulation; research on controlling the quality of cell therapy production | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by TREEFROG THERAPEUTICS
- Other trademarks owned by TREEFROG THERAPEUTICS
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named TREEFROG THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 21, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 21, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 16, 2026 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jul 15, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 1, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jul 1, 2026 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jun 19, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 19, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 19, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 19, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 19, 2026 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jan 8, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 20, 2025 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 19, 2025 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 11, 2025 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 10, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 7, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 5, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 2, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |